Now Available: Spotlight on Alamar Biosciences CEO Yuling Luo. Click here to read.
Stilla Technologies, the start-up leading innovations in digital PCR, announced it has closed a $26.5 million Series C financing.
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today it has extended its Series A financing round with an additional close of $25.5 million, bringing the total Series A amount raised to $59.5 million.
Iambic’s unique AI-Driven drug-discovery platform identifies potential first-in-class and best-in-class development candidates years faster than industry norms. Funding will support continued AI platform innovations and advancement of multiple candidates into clinical development, Including IAM-H1, a selective brain-penetrant HER2 Inhibitor, and IAM-C1, a selective dual CDK2/4 inhibitor.
Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners...
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
